Calculating The Intrinsic Value Of Nippon Shinyaku Co., Ltd. (TSE:4516)
Key Insights
- The projected fair value for Nippon Shinyaku is JP¥2,866 based on Dividend Discount Model
- With JP¥3,255 share price, Nippon Shinyaku appears to be trading close to its estimated fair value
- Analyst price target for 4516 is JP¥3,987, which is 39% above our fair value estimate
Today we will run through one way of estimating the intrinsic value of Nippon Shinyaku Co., Ltd. (TSE:4516) by taking the forecast future cash flows of the company and discounting them back to today's value. The Discounted Cash Flow (DCF) model is the tool we will apply to do this. It may sound complicated, but actually it is quite simple!
Companies can be valued in a lot of ways, so we would point out that a DCF is not perfect for every situation. Anyone interested in learning a bit more about intrinsic value should have a read of the Simply Wall St analysis model.
See our latest analysis for Nippon Shinyaku
The Method
As Nippon Shinyaku operates in the pharmaceuticals sector, we need to calculate the intrinsic value slightly differently. In this approach dividends per share (DPS) are used, as free cash flow is difficult to estimate and often not reported by analysts. Unless a company pays out the majority of its FCF as a dividend, this method will typically underestimate the value of the stock. The 'Gordon Growth Model' is used, which simply assumes that dividend payments will continue to increase at a sustainable growth rate forever. For a number of reasons a very conservative growth rate is used that cannot exceed that of a company's Gross Domestic Product (GDP). In this case we used the 5-year average of the 10-year government bond yield (0.2%). The expected dividend per share is then discounted to today's value at a cost of equity of 4.7%. Relative to the current share price of JP¥3.3k, the company appears around fair value at the time of writing. Valuations are imprecise instruments though, rather like a telescope - move a few degrees and end up in a different galaxy. Do keep this in mind.
Value Per Share = Expected Dividend Per Share / (Discount Rate - Perpetual Growth Rate)
= JP¥129 / (4.7% – 0.2%)
= JP¥2.9k
Important Assumptions
The calculation above is very dependent on two assumptions. The first is the discount rate and the other is the cash flows. Part of investing is coming up with your own evaluation of a company's future performance, so try the calculation yourself and check your own assumptions. The DCF also does not consider the possible cyclicality of an industry, or a company's future capital requirements, so it does not give a full picture of a company's potential performance. Given that we are looking at Nippon Shinyaku as potential shareholders, the cost of equity is used as the discount rate, rather than the cost of capital (or weighted average cost of capital, WACC) which accounts for debt. In this calculation we've used 4.7%, which is based on a levered beta of 0.800. Beta is a measure of a stock's volatility, compared to the market as a whole. We get our beta from the industry average beta of globally comparable companies, with an imposed limit between 0.8 and 2.0, which is a reasonable range for a stable business.
SWOT Analysis for Nippon Shinyaku
- Earnings growth over the past year exceeded its 5-year average.
- Currently debt free.
- Dividend is in the top 25% of dividend payers in the market.
- Earnings growth over the past year underperformed the Pharmaceuticals industry.
- Good value based on P/E ratio compared to estimated Fair P/E ratio.
- Dividends are not covered by cash flow.
- Annual earnings are forecast to decline for the next 3 years.
Next Steps:
Although the valuation of a company is important, it shouldn't be the only metric you look at when researching a company. It's not possible to obtain a foolproof valuation with a DCF model. Rather it should be seen as a guide to "what assumptions need to be true for this stock to be under/overvalued?" For instance, if the terminal value growth rate is adjusted slightly, it can dramatically alter the overall result. For Nippon Shinyaku, there are three important aspects you should further research:
- Risks: To that end, you should learn about the 3 warning signs we've spotted with Nippon Shinyaku (including 2 which make us uncomfortable) .
- Future Earnings: How does 4516's growth rate compare to its peers and the wider market? Dig deeper into the analyst consensus number for the upcoming years by interacting with our free analyst growth expectation chart.
- Other High Quality Alternatives: Do you like a good all-rounder? Explore our interactive list of high quality stocks to get an idea of what else is out there you may be missing!
PS. The Simply Wall St app conducts a discounted cash flow valuation for every stock on the TSE every day. If you want to find the calculation for other stocks just search here.
Valuation is complex, but we're here to simplify it.
Discover if Nippon Shinyaku might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.
Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
About TSE:4516
Nippon Shinyaku
Manufactures and sells pharmaceuticals and foodstuffs in Japan and internationally.
Flawless balance sheet with proven track record and pays a dividend.